pristane has been researched along with Acute Kidney Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bona, SR; Bonomini, F; Dos Santos, M; Favero, G; Marroni, NP; Montanari, CC; Poletti, PT; Rezzani, R; Stacchiotti, A; Veronese, FV | 1 |
| Balazs, M; Caplazi, P; DeForge, L; Lee, WP; Lin, W; Lin, Z; Martin, F; McVay, S; Nguyen, A; Seshasayee, D; Sun, Y; Suto, E; Zarrin, AA | 1 |
2 other study(ies) available for pristane and Acute Kidney Failure
| Article | Year |
|---|---|
Protective effects of quercetin treatment in a pristane-induced mouse model of lupus nephritis.
Topics: Acute Kidney Injury; Animals; Antioxidants; Catalase; Cytokines; Disease Models, Animal; Female; Inflammation; Kidney Glomerulus; Lupus Nephritis; Mice; Mice, Inbred BALB C; Oxidative Stress; Proteinuria; Quercetin; Superoxide Dismutase-1; Terpenes | 2018 |
Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.
Topics: Acute Kidney Injury; Animals; Antibodies, Monoclonal; Antigens, CD20; Autoantibodies; B-Cell Activating Factor; B-Cell Activation Factor Receptor; B-Lymphocytes; Cell Count; Disease Models, Animal; Female; Immunotherapy; Incidence; Interferon-alpha; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Terpenes; Treatment Outcome | 2015 |